I
International Stem Cell Corporation
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products.
About International Stem Cell Corporation
International Stem Cell Corporation (OTC: ISCO) is a clinical-stage biotechnology firm that has developed a proprietary method for creating human pluripotent stem cells (hpSCs) from unfertilized eggs, a process known as parthenogenesis. This approach avoids the ethical controversies associated with fertilized embryos and has the potential to create immune-matched cells for broad populations, addressing the critical issue of transplant rejection. The company's scientific focus is on developing therapies for severe diseases of the central nervous system, joints, and liver. Its most advanced program targets Parkinson's disease, leveraging its patented method for manufacturing clinical-grade neural stem cells (ISC-hpNSC®).
The company's management team includes CEO & Co-Chairman Dr. Andrey Semechkin, a specialist in system analysis and corporate management with over two decades of experience across various industries. Dr. Russell Kern, the Executive Vice President and Chief Scientific Officer, has extensive expertise in medical genetics, embryology, and stem cell biology, particularly in neuroscience and Parkinson's disease research. ISCO operates through a dual-pronged business model. While its primary focus is on long-term therapeutic development, it generates revenue through two wholly-owned subsidiaries. Lifeline Cell Technology (LCT), founded by individuals with over 25 years of experience in cell culture, provides high-quality primary human cells, specialized culture media, and reagents to researchers at pharmaceutical companies, academic institutions, and government labs. Lifeline Skin Care, launched in 2010, markets a line of anti-aging cosmeceutical products that utilize extracts from the company's non-embryonic human stem cells.
Financially, the company's commercial businesses provide a revenue stream to partially offset research and development expenditures. For the fiscal year 2024, ISCO reported revenues of $9.1 million, an increase from $7.8 million in the previous year, primarily driven by sales in its biomedical segment. Despite a gross profit of $5.3 million, the company recorded a net loss of $209,000 for 2024 and acknowledges the need for additional capital to fund its ongoing operations and clinical trials. Historically, the company has secured funding through private placements. Milestones include creating human cornea-compatible tissue in 2007, establishing the UniStemCell™ bank in 2010, and completing the cell bank for its Parkinson's disease clinical trial in 2015.
Source: Dealroom company dataNews
Open roles
International Stem Cell Corporation in the San Diego ecosystem
The International Stem Cell Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about International Stem Cell Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See International Stem Cell Corporation on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


